{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:20:29Z","timestamp":1789842029514,"version":"4.0.1"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Polish Lymphoma Research Group"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ctrv.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T11:17:51Z","timestamp":1560943071000},"page":"44-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["The role of PET\/CT in the modern treatment of Hodgkin lymphoma"],"prefix":"10.1016","volume":"77","author":[{"given":"Jan Maciej","family":"Zaucha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4394-5031","authenticated-orcid":false,"given":"Stephane","family":"Chauvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Zaucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Biggii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2019.06.002_b0005","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.06.002_b0010","series-title":"PET scan in Hodgkin Lymphoma. Role in Diagnosis, Prognosis and Treatment. Edited by Gallamini A: Springer","first-page":"1","article-title":"PET\/CT for HL staging","author":"Hutchings","year":"2016"},{"key":"10.1016\/j.ctrv.2019.06.002_b0015","first-page":"482","article-title":"Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma","volume":"91","author":"Hutchings","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2019.06.002_b0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3109\/10428194.2014.919635","article-title":"Comparison of positron emission tomography\/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma","volume":"56","author":"Bednaruk-Mlynski","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2019.06.002_b0025","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0030","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/asheducation-2017.1.310","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"2017","author":"Liu","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ctrv.2019.06.002_b0035","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2007-09-112128","article-title":"Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes","volume":"111","author":"Ma","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0040","first-page":"475","article-title":"The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease","volume":"91","author":"Gallamini","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2019.06.002_b0045","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1158\/0008-5472.CAN-05-0100","article-title":"Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor","volume":"65","author":"Weihrauch","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.06.002_b0050","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3324\/haematol.2011.053199","article-title":"Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma","volume":"97","author":"Plattel","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2019.06.002_b0055","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0060","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2967\/jnumed.115.158402","article-title":"Summary of the UPICT protocol for 18F-FDG PET\/CT imaging in oncology clinical trials","volume":"56","author":"Graham","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0065","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1259\/bjr\/24661539","article-title":"A novel approach for reduction of brown fat uptake on FDG PET","volume":"82","author":"Agrawal","year":"2009","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0070","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first International workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.ctrv.2019.06.002_b0075","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1023\/A:1008486928190","article-title":"Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease","volume":"9","author":"Bangerter","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0080","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1023\/A:1008368330519","article-title":"2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution","volume":"11","author":"Partridge","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0085","first-page":"266","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease","volume":"86","author":"Jerusalem","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2019.06.002_b0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00277-001-0390-y","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease","volume":"81","author":"Weihrauch","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0095","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/annonc\/mdh426","article-title":"Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease","volume":"15","author":"Munker","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0100","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.bjc.6601561","article-title":"Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma","volume":"90","author":"Naumann","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2019.06.002_b0105","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-007-0356-9","article-title":"Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi","volume":"86","author":"Rigacci","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0110","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0115","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V91.9.3340","article-title":"Detection of lymphoma in bone marrow by whole-body positron emission tomography","volume":"91","author":"Carr","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0120","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2967\/jnumed.116.184218","article-title":"Prognostic value of bone marrow tracer uptake pattern in baseline PET scans in Hodgkin lymphoma: results from an international collaborative study","volume":"58","author":"Zwarthoed","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0125","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00259-014-2706-x","article-title":"Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET\/CT","volume":"41","author":"Weiler-Sagie","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ctrv.2019.06.002_b0130","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-015-2529-2","article-title":"Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0140","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0145","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/annonc\/mdq403","article-title":"Fused FDG-PET\/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen","volume":"22","author":"Picardi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0150","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/1097-0142(19880415)61:8<1719::AID-CNCR2820610834>3.0.CO;2-A","article-title":"Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment","volume":"61","author":"Specht","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2019.06.002_b0155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.semnuclmed.2017.09.005","article-title":"Metabolic tumor volume metrics in lymphoma","volume":"48","author":"Kostakoglu","year":"2018","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0160","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1200\/JCO.2001.19.5.1388","article-title":"Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance","volume":"19","author":"Gobbi","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0165","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","author":"Kanoun","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ctrv.2019.06.002_b0170","doi-asserted-by":"crossref","first-page":"e0140830","DOI":"10.1371\/journal.pone.0140830","article-title":"Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in hodgkin lymphoma","volume":"10","author":"Kanoun","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.06.002_b0175","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/cas.12282","article-title":"Metabolic tumor volume by positron emission tomography\/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma","volume":"104","author":"Song","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2019.06.002_b0180","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","article-title":"Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation","volume":"131","author":"Akhtari","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0185","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0190","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1200\/JCO.2016.34.15_suppl.7509","article-title":"Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial","volume":"34","author":"Casasnovas","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2967\/jnumed.118.210047","article-title":"Metabolic tumour volume for response prediction in advanced-stage hodgkin lymphoma","volume":"60","author":"Mettler","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0200","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0205","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbmt.2017.09.006","article-title":"Positron emission tomography-based assessment of metabolic tumor volume predicts survival after autologous hematopoietic cell transplantation for Hodgkin lymphoma","volume":"24","author":"Prochazka","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2019.06.002_b0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40336-015-0135-x","article-title":"PET-derived metabolic volume metrics in lymphoma","volume":"3","author":"Kostakoglu","year":"2015","journal-title":"Clin. Transl Imag"},{"key":"10.1016\/j.ctrv.2019.06.002_b0215","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients","volume":"41","author":"Meignan","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ctrv.2019.06.002_b0220","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2967\/jnumed.109.066241","article-title":"Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET","volume":"51","author":"Tylski","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0225","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging subcommittee of International harmonization project in lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0230","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0235","first-page":"522","article-title":"18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review","volume":"91","author":"Zijlstra","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2019.06.002_b0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2967\/jnumed.107.039867","article-title":"18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review","volume":"49","author":"Terasawa","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0245","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2967\/jnumed.107.046292","article-title":"18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?","volume":"49","author":"Juweid","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0250","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0255","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/10428190701422414","article-title":"Hodgkin lymphoma: response assessment by revised International workshop criteria","volume":"48","author":"Brepoels","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2019.06.002_b0260","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/annonc\/mdp522","article-title":"Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study","volume":"21","author":"Mocikova","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0265","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00259-016-3390-9","article-title":"Diagnostic accuracy of FDG PET\/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville criteria (DC) and the International harmonization project criteria (IHPC)","volume":"43","author":"Fallanca","year":"2016","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ctrv.2019.06.002_b0270","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3109\/10428190903308072","article-title":"Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation","volume":"50","author":"Gallamini","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2019.06.002_b0275","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim pet in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0280","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/10428190009113384","article-title":"18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's lymphoma-comparison with CT","volume":"39","author":"Mikhaeel","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2019.06.002_b0285","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1007\/s00259-011-1741-0","article-title":"Prognostic value of interim FDG PET\/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International harmonization project (IHP), Gallamini and London criteria","volume":"38","author":"Le Roux","year":"2011","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ctrv.2019.06.002_b0290","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdi200","article-title":"Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma","volume":"16","author":"Hutchings","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0295","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","author":"Gallamini","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2019.06.002_b0300","first-page":"27","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"27","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ctrv.2019.06.002_b0305","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1093\/annonc\/mdx524","article-title":"The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the polish lymphoma research group (PLRG) observational study","volume":"28","author":"Zaucha","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0310","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2018-05-852129","article-title":"Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma","volume":"132","author":"Kobe","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0315","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0320","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","article-title":"Role of functional imaging in the management of lymphoma","volume":"29","author":"Cheson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0325","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0330","first-page":"1706","article-title":"Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy","volume":"34","author":"Hoekstra","year":"1993","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0335","first-page":"1018","article-title":"PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease","volume":"43","author":"Kostakoglu","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0340","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00259-003-1333-8","article-title":"Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma","volume":"31","author":"Torizuka","year":"2004","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ctrv.2019.06.002_b0345","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/1042819031000149430","article-title":"FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison","volume":"45","author":"Friedberg","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2019.06.002_b0350","first-page":"4464","article-title":"Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose","volume":"91","author":"R\u00f6mer","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0355","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/cncr.22276","article-title":"FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease","volume":"107","author":"Kostakoglu","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2019.06.002_b0360","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to International prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0365","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.2008.16.0861","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review","volume":"27","author":"Terasawa","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0370","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00259-011-1916-8","article-title":"Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients","volume":"39","author":"Zinzani","year":"2012","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ctrv.2019.06.002_b0375","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","article-title":"18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma","volume":"51","author":"Cerci","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0380","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0385","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0390","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0395","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0400","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0405","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2019.06.002_b0410","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/annonc\/mdn768","article-title":"FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value","volume":"20","author":"Markova","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0415","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","volume":"18","author":"Borchmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0420","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/annonc\/mdq549","article-title":"End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0425","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3109\/10428194.2012.735667","article-title":"Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy","volume":"54","author":"Filippi","year":"2013","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.ctrv.2019.06.002_b0430","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/annonc\/mdp071","article-title":"Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy","volume":"20","author":"Sher","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0435","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.23994","article-title":"The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL)","volume":"90","author":"Rigacci","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0440","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2015.04.021","article-title":"Interim PET after two ABVD cycles in early-stage Hodgkin lymphoma: outcomes following the continuation of chemotherapy plus radiotherapy","volume":"92","author":"Simontacchi","year":"2015","journal-title":"Int J Radiat Oncol \u2022 Biol \u2022 Phys"},{"key":"10.1016\/j.ctrv.2019.06.002_b0445","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2013.53.2838","article-title":"In vivo treatment sensitivity testing with positron emission tomography\/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma","volume":"32","author":"Hutchings","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0450","first-page":"135","article-title":"The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease","volume":"2014","author":"Evens","year":"2014","journal-title":"ASH Educat Program Book"},{"key":"10.1016\/j.ctrv.2019.06.002_b0455","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2018-99-114519","article-title":"PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase 3 trial HD16 by the German Hodgkin study group","volume":"132","author":"Fuchs","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0460","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2010.08485.x","article-title":"Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses","volume":"152","author":"Gallamini","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0465","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/0284186X.2013.862344","article-title":"Early treatment intensification with escalated BEACOPP in patients with Hodgkins lymphoma not responding to ABVD therapy","volume":"53","author":"Danielewicz","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0470","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.14734","article-title":"Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET\/CT is beneficial: a prospective multicentre trial of 355 patients","volume":"178","author":"Dann","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0475","article-title":"Early chemotherapy de-escalation strategy in advanced-stage Hodgkin lymphoma patients with negative positron emission tomography scan after two escalated BEACOPP cycles","author":"Dlugosz-Danecka","year":"2019","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0480","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2019.06.002_b0485","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk Up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0490","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0495","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0500","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0505","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0510","doi-asserted-by":"crossref","first-page":"20150983","DOI":"10.1259\/bjr.20150983","article-title":"Post-ABVD\/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients","volume":"89","author":"Ciammella","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0515","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/bjh.14902","article-title":"Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?","volume":"179","author":"Milgrom","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0520","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/bjh.13943","article-title":"No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study","volume":"173","author":"Jakobsen","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0525","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0530","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bjh.12824","article-title":"F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"165","author":"Gentzler","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0535","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","article-title":"Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation","volume":"17","author":"Smeltzer","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2019.06.002_b0540","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","article-title":"Prognostic value of pretransplant FDG-PET in refractory\/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0545","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/bmt.2017.143","article-title":"Pre-autologous transplantation PET\/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma","volume":"52","author":"Damlaj","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2019.06.002_b0550","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"Brockelmann","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0555","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.bbmt.2016.03.034","article-title":"Impact of pretransplantation (18)F-fluorodeoxyglucose-positron emission tomography on survival outcomes after T Cell-depleted allogeneic transplantation for Hodgkin lymphoma","volume":"22","author":"Reyal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2019.06.002_b0560","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0565","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3109\/10428194.2013.819575","article-title":"18-Fluorodeoxyglucose positron emission tomography\/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma","volume":"55","author":"Kahraman","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2019.06.002_b0570","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0575","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.14808","article-title":"Pulmonary sarcoid-like granulomatosis induced by nivolumab","volume":"176","author":"Montaudie","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0580","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/annonc\/mdw125","article-title":"Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab","volume":"27","author":"Cousin","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0585","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","article-title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study","volume":"3","author":"Agostinelli","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0590","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cam4.585","article-title":"CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma","volume":"5","author":"Cuccaro","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0595","first-page":"307","article-title":"Genotyping of classical Hodgkin lymphoma on the liquid biopsy","volume":"130","author":"Spina","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.06.002_b0600","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","article-title":"Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients","volume":"55","author":"Rossi","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.06.002_b0605","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ctrv.2019.06.002_b0610","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hon.2437_18","article-title":"Can baseline pet-ct features predict outcomes in advanced Hodgkin lymphoma? a prospective evaluation of uk patients in the rathl trial (CRUK\/07\/033)","volume":"35","author":"Pike","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0615","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2016.69.3747","article-title":"Metabolic tumor volume in lymphoma: hype or hope?","volume":"34","author":"Sch\u00f6der","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0620","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.ctrv.2019.06.002_b0625","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1002\/mp.12349","article-title":"Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas","volume":"44","author":"Ben Bouallegue","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.ctrv.2019.06.002_b0630","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/annonc\/mdl122","article-title":"Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients","volume":"17","author":"Zinzani","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.002_b0635","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1182\/blood-2010-10-314260","article-title":"Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I\/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET","volume":"117","author":"Straus","year":"2011","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219300805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219300805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:21:35Z","timestamp":1759656095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737219300805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":127,"alternative-id":["S0305737219300805"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.06.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of PET\/CT in the modern treatment of Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}